Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917274 | 0.94 | TSHR (0.45) | ALDH1A1TSHRMAPK1GAACYP2C19 | |
| SCHEMBL24619078 | 0.94 | TSHR (0.45) | ALDH1A1TSHRMAPK1GAACYP2C19 | |
| SCHEMBL2625515 | 0.86 | TP53 (0.39) | ALDH1A1TSHRMAPK1ATMGAA | |
| SCHEMBL1104713 | 0.86 | TP53 (0.39) | ALDH1A1TSHRMAPK1ATMGAA | |
| SCHEMBL12384404 | 0.86 | TP53 (0.39) | ALDH1A1TSHRMAPK1ATMGAA | |
| SCHEMBL18745363 | 0.80 | TSHR (0.43) | ALDH1A1TSHRMAPK1GAACYP2C19 | |
| SCHEMBL13225930 | 0.79 | FABP6 (0.43) | ALDH1A1TSHRMAPK1ATMGAA | |
| SCHEMBL15177622 | 0.78 | PAX8 (0.32) | ALDH1A1TSHRATM | |
| SCHEMBL21936034 | 0.77 | GAA (0.42) | ALDH1A1TSHRMAPK1ATMGAA | |
| SCHEMBL18531901 | 0.74 | EPHX1 (0.36) | ALDH1A1TSHRMAPK1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | ALDH1A1 3682/4885TSHR 3700/4885MAPK1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.